Jul. 4 at 5:44 PM
$IOVA
Fred on IOV-5001 program at Jefferies - One of the many exciting pieces inside the pipeline at Iovance -
“IL-12 is a cytokine that's been in everybody's mind for the last 40 years as one of the most powerful cytokines to potentially achieve an anticancer response…
We think it has the potential to turn immunologically cold tumors hot…
It really could expand the platform to hundreds of thousands of patients, and this is something you can't do with a bispecific, you can't do it with a T-cell engager. There's nothing else out there for these patients that works like this. If this works, it could truly be the game changer. That's why we're so excited about it.”
This along with Endometrial, Sarcomas, NSCLC, Frontline melanoma, Gen 3 manufacturing process taking TIL process from ~32 days to 16, improved efficiency & decreased toxicity through IOV-4001 and 3001, ex us expansions,
$0 debt, 100% ownership….
Dilution is temporary. Iovance has an exciting road ahead.
